Rhumbline Advisers Decreases Holdings in Exelixis, Inc. $EXEL

Rhumbline Advisers trimmed its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 3.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 749,216 shares of the biotechnology company’s stock after selling 27,580 shares during the quarter. Rhumbline Advisers owned 0.28% of Exelixis worth $30,943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Exelixis by 81.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after purchasing an additional 19,407 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Exelixis by 4.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock worth $54,153,000 after purchasing an additional 68,133 shares during the period. Focus Partners Wealth boosted its holdings in shares of Exelixis by 83.4% in the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after buying an additional 17,483 shares during the last quarter. Geneos Wealth Management Inc. boosted its holdings in shares of Exelixis by 134.3% in the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after buying an additional 944 shares during the last quarter. Finally, Sivia Capital Partners LLC grew its position in Exelixis by 23.8% during the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock valued at $633,000 after buying an additional 2,764 shares during the period. Institutional investors own 85.27% of the company’s stock.

Insider Activity at Exelixis

In related news, EVP Patrick J. Haley sold 34,187 shares of the firm’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $41.88, for a total transaction of $1,431,751.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 72,230 shares of company stock valued at $3,046,923 over the last quarter. 2.85% of the stock is currently owned by insiders.

Exelixis Stock Up 2.9%

NASDAQ EXEL opened at $43.92 on Monday. Exelixis, Inc. has a twelve month low of $32.38 and a twelve month high of $49.62. The business has a 50-day moving average price of $43.62 and a 200-day moving average price of $41.00. The firm has a market cap of $11.41 billion, a price-to-earnings ratio of 15.86, a price-to-earnings-growth ratio of 0.99 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The company had revenue of $598.66 million for the quarter, compared to the consensus estimate of $609.17 million. During the same quarter last year, the company earned $0.55 EPS. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. Research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Zacks Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Wells Fargo & Company raised their target price on Exelixis from $30.00 to $35.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. Bank of America lowered Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price target for the company. in a report on Monday, January 5th. Wolfe Research initiated coverage on Exelixis in a research report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Finally, Citigroup cut Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $47.11.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.